The Journal of Bone and Joint Surgery (American). 2005;87:1367-1378.
doi:10.2106/JBJS.D.02585
© 2005 The Journal of Bone and Joint Surgery, Inc.
Bone Morphogenetic Proteins
Development and Clinical Efficacy in the Treatment of Fractures and Bone Defects
M.F. Termaat, MD1,
F.C. Den Boer, MD, PhD2,
F.C. Bakker, MD, PhD1,
P. Patka, MD, PhD1 and
H.J.Th.M. Haarman, MD, PhD1
1 Department of Surgery and Traumatology, VU University Medical Center, P.O. Box
7057, 1007 MB Amsterdam, The Netherlands. E-mail address for M.F. Termaat:
mf.termaat{at}vumc.nl.
E-mail address for F.C. Bakker:
fc.bakker{at}vumc.nl.
E-mail address for P. Patka:
p.patka{at}vumc.nl.
E-mail address for H.J.Th.M. Haarman:
hjtm.haarman{at}vumc.nl
2 Department of Surgery, Sint Antonius Hospital, P.O. Box 2500, 3430 EM
Nieuwegein, The Netherlands. E-mail address:
frankdenboer{at}hotmail.com
Investigation performed at the Department of Surgery and Traumatology,
VU University Medical Center, Amsterdam, The Netherlands
The discovery of bone morphogenetic proteins marks a major step forward in
the understanding of bone physiology and in the development of advanced
methods in skeletal surgery.
The cornerstones for successful growth-factor therapy in skeletal surgery
remain biomechanical stability and biological vitality of the bone providing
an adequate environment for new bone formation.
Knowledge of the biological characteristics, mechanisms of action, and
methods of delivery of growth factors will become essential for skeletal
surgeons.
The current clinical application of bone morphogenetic proteins is safe and
efficacious as a result of a well-regulated cascade of events leading to bone
formation.
Clinical trials have not yet determined whether different clinical
indications each require a specific bone-tissue-engineering format or if a
single pathway for stimulating bone-healing with growth factors is
sufficient.

CiteULike Connotea Del.icio.us Facebook Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. S. Richards, M. E. Oetgen, and C. E. Johnston
The Use of rhBMP-2 for the Treatment of Congenital Pseudarthrosis of the Tibia: A Case Series
J. Bone Joint Surg. Am.,
January 1, 2010;
92(1):
177 - 185.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Vander Have, R. N. Hensinger, M. Caird, C. Johnston, and F. A. Farley
Congenital Pseudarthrosis of the Tibia
J. Am. Acad. Ortho. Surg.,
April 1, 2008;
16(4):
228 - 236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. G. Zalavras, R. E. Marcus, L. S. Levin, and M. J. Patzakis
Management of open fractures and subsequent complications.
J. Bone Joint Surg. Am.,
April 1, 2007;
89(4):
884 - 895.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Seeherman, K. Azari, S. Bidic, L. Rogers, X. J. Li, J. O. Hollinger, and J. M. Wozney
rhBMP-2 Delivered in a Calcium Phosphate Cement Accelerates Bridging of Critical-Sized Defects in Rabbit Radii
J. Bone Joint Surg. Am.,
July 1, 2006;
88(7):
1553 - 1565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wang, C. C. Clark, and C. T. Brighton
Up-Regulation of Bone Morphogenetic Proteins in Cultured Murine Bone Cells with Use of Specific Electric Fields
J. Bone Joint Surg. Am.,
May 1, 2006;
88(5):
1053 - 1065.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|